DK3562821T3 - Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase - Google Patents

Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase Download PDF

Info

Publication number
DK3562821T3
DK3562821T3 DK17829043.3T DK17829043T DK3562821T3 DK 3562821 T3 DK3562821 T3 DK 3562821T3 DK 17829043 T DK17829043 T DK 17829043T DK 3562821 T3 DK3562821 T3 DK 3562821T3
Authority
DK
Denmark
Prior art keywords
galactosidase
beta
activity
preparation
methods
Prior art date
Application number
DK17829043.3T
Other languages
Danish (da)
English (en)
Inventor
Jordà Elena Cubero
Alonso Xavier Barril
COLLAZO Ana Maria GARCÍA
Pedemonte Marc Martinell
Pascau Laura Pilar Rodriguez
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Application granted granted Critical
Publication of DK3562821T3 publication Critical patent/DK3562821T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17829043.3T 2016-12-28 2017-12-27 Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase DK3562821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382660 2016-12-28
PCT/IB2017/058438 WO2018122746A1 (en) 2016-12-28 2017-12-27 Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase

Publications (1)

Publication Number Publication Date
DK3562821T3 true DK3562821T3 (da) 2021-02-15

Family

ID=57777485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17829043.3T DK3562821T3 (da) 2016-12-28 2017-12-27 Isoquinolinforbindelser, fremgangsmåder til fremstilling af disse og terapeutiske anvendelser af disse ved tilstande associeret med ændringen i aktiviteten af beta-galactosidase

Country Status (13)

Country Link
US (1) US11440898B2 (cg-RX-API-DMAC10.html)
EP (1) EP3562821B9 (cg-RX-API-DMAC10.html)
JP (1) JP7144863B2 (cg-RX-API-DMAC10.html)
CN (1) CN110494432B (cg-RX-API-DMAC10.html)
AU (1) AU2017388300B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019013593A2 (cg-RX-API-DMAC10.html)
CA (1) CA3047700A1 (cg-RX-API-DMAC10.html)
DK (1) DK3562821T3 (cg-RX-API-DMAC10.html)
ES (1) ES2862374T3 (cg-RX-API-DMAC10.html)
IL (1) IL267553B (cg-RX-API-DMAC10.html)
PL (1) PL3562821T3 (cg-RX-API-DMAC10.html)
PT (1) PT3562821T (cg-RX-API-DMAC10.html)
WO (1) WO2018122746A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023042177A1 (en) 2021-09-20 2023-03-23 Gt Gain Therapeutics Sa Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide
CN122122139A (zh) * 2023-11-02 2026-05-29 Gt增益治疗股份有限公司 取代的吲哚基化合物、其组合物及其治疗用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2001058899A1 (en) 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
EP1433776B1 (en) 2001-09-07 2011-01-19 Seikagaku Corporation Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient
JP2006519258A (ja) 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2005070929A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Akt活性のある阻害剤
CA2555914A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
WO2006058201A2 (en) * 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
AU2006204750C1 (en) 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
JP2010500330A (ja) 2006-08-10 2010-01-07 フエルレル インターナショナル,ソシエダッド アノニマ Gabaa受容体に対して親和性を有する1h−キノリン−4−オン化合物、方法、使用及び組成物
EP1903034A1 (en) 2006-09-19 2008-03-26 Technische Universität Graz Iminosugar glycoconjugates
WO2009042294A2 (en) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
WO2009049422A1 (en) 2007-10-18 2009-04-23 The Hospital For Sick Children Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
CN102743385B (zh) * 2007-11-16 2014-09-17 沃泰克斯药物股份有限公司 Atp结合盒转运蛋白的异喹啉调节剂
ES2337435B8 (es) 2008-10-22 2011-07-19 Consejo Superior De Investigaciones Cientificas (Csic) (25%) Compuestos potenciadores de la actividad de glicosidasas mutantes.
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
WO2011049737A1 (en) 2009-10-19 2011-04-28 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
LT2685986T (lt) 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
WO2013005168A2 (en) * 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators
SG11201402765TA (en) * 2011-12-30 2014-06-27 Hanmi Pharm Ind Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
CA2883386A1 (en) * 2012-09-14 2014-03-20 Eternity Bioscience Inc. Aminoisoquinoline derivatives as protein kinase inhibitors
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
EP3027590A1 (en) * 2013-07-31 2016-06-08 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
AU2014347027A1 (en) 2013-11-06 2016-06-23 Bristol-Myers Squibb Company GSK -3 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
JP6239149B2 (ja) 2014-04-25 2017-11-29 ファイザー・インク 複素芳香族化合物およびそのドーパミンd1リガンドとしての使用
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016120808A1 (en) * 2015-01-28 2016-08-04 Minoryx Therapeutics S.L. Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2017388300A1 (en) 2019-07-11
AU2017388300B2 (en) 2022-03-31
CA3047700A1 (en) 2018-07-05
JP7144863B2 (ja) 2022-09-30
IL267553B (en) 2021-10-31
ES2862374T3 (es) 2021-10-07
CN110494432A (zh) 2019-11-22
IL267553A (en) 2019-08-29
EP3562821B9 (en) 2021-05-26
JP2020514284A (ja) 2020-05-21
PL3562821T3 (pl) 2021-06-14
WO2018122746A1 (en) 2018-07-05
US20200071294A1 (en) 2020-03-05
EP3562821A1 (en) 2019-11-06
CN110494432B (zh) 2022-08-12
EP3562821B1 (en) 2020-12-02
BR112019013593A2 (pt) 2020-01-07
PT3562821T (pt) 2021-03-03
US11440898B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
IL259534A (en) Structures for microfluidic isolation are produced at the place of assembly, kits and their uses
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
IL257486A (en) Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
DK3253865T3 (da) Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller
DK3207130T3 (da) Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
DK3185854T3 (da) Injicerbare opslæmninger og fremgangsmåder til fremstilling og anvendelse af disse
DK3303317T3 (da) Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3377484T3 (da) Fremgangsmåder til behandling af multipel sklerose under anvendelse af pyrimidin- og pyridinforbindelser med btk- inhiberende aktivitet
DK2951754T3 (da) Fremgangsmåder, systemer og software til identifikation af biomolekyler med interagerende komponenter
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK2968418T3 (da) Præparater afledt af placentamaterialer til fremstilling og anvendelse deraf
EP3680332C0 (en) SAMPLE PREPARATION SYSTEM AND CARTRIDGE
IL247458A0 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
DK3467904T3 (da) Separator med høj vådbarhed og fremgangsmåde til fremstilling deraf
DK3386523T3 (da) Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme
DK3348557T3 (da) Imidazo[1,2-a]pyridiner til behandling eller forebyggelse af hyperurekæmi eller gigt
DK3247352T3 (da) Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion